Sitala Bio

Executive Summary

Sitala Bio is a UK-based private biotechnology company founded in 2021, focused on developing small molecule therapeutics to address chronic low-grade inflammation driven by aging immune systems. The company's approach targets the root cause of inflammatory diseases in the brain and body, which are exacerbated by longer lifespans. By modulating immune responses, Sitala Bio aims to treat a range of age-related inflammatory conditions. Despite limited public information on its pipeline or funding, the company's scientific premise aligns with emerging trends in immunology and aging research.